New research indicates that maintaining meaningful weight loss after starting GLP-1-based therapies could play an important role in reducing the risk of multiple obesity-related diseases. Popular weight loss drugs such as semaglutide (Ozempic, Wegovy, and Rybelsus) and tirzepatide (Mounjaro and Zepbound) may do more than help people lose weight. New research suggests the amount of [...]from SciTechDaily https://ift.tt/0LKFe6W
